West Pharmaceutical Services, Inc.June 2016

Cautionary Statement Under the Private Securities Litigation Reform Act of 1995This slide presentation and any accompanying management commentary contain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product development and operational performance.Each of these statements is based on preliminary information, and actual results could differ from any preliminary estimates. We caution investors that the risk factors listed under Cautionary Statement in our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially from those estimated or predicted in the forward-looking statements. You should evaluate any statement in light of these important factors. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Non-U.S. GAAP Financial MeasuresCertain financial measures included in these presentation materials, or which may be referred to in managements discussion of the Companys results and outlook, have not been calculated in accordance with U.S. generally accepted accounting principles (U.S. GAAP), and therefore are referred to as non-GAAP financial measures. Non-GAAP financial measures should not be considered in isolation or as an alternative to such measures determined in accordance with GAAP. Please refer to Reconciliation of Non-GAAP Measures at the end of these materials for more information.

TrademarksRegistered trademarks used in this report are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless noted otherwise. Daikyo Crystal Zenith is a registered trademark of Daikyo Seiko, Ltd. Verux Brand and the logo are trademarks of West Pharmaceutical Services Singapore Pte. Ltd. in Singapore and other jurisdictions.

Safe harbor statement

2

By your side

Pharmaceutical, biotechnology, generic and medical device companies trust West and our ability to deliver consistent high quality and technologically advanced containment and delivery solutions.

We share their commitment to improving health for patients worldwide.

Our mission

3

Become the world leader in integrated containment and delivery of injectable medicines

4

Injectable market

30 Billion Units

$284 Billion of Annual

Drug Sales

$7-8 BillionContainment &

Delivery Product SalesSource: IMS and Company estimates

An integral part of the healthcare industry

Top 35Injectable biologics rely on West and

Daikyo components

~ 40 BillionComponents manufactured

annually

Top 75Supplier to the top 75

pharmaceutical & biotech injectable companies

5

Components manufactured

6

Every Dose | Every Time | 100% Commitment

40 BillionANNUALLY

110 MillionPER DAY

5 MillionPER HOUR

76,000PER MINUTE

2015 Sales$1.4 billion

2015 Sales$1.4 billion

2015 Net Sales by Geography

West business at a glance

7%

39%

33%21%

Americas

Europe, Middle East, Africa

Asia Pacific

2015 Net Sales by Category

2016E Sales(*)by Market Group

53%40%

7%

High-Value Components

Standard Packaging

Delivery Devices

Contract Manufacturing

PRO

PRIE

TARY

PR

ODU

CTS

Pharma

Generics

Biologics

Contract Manufacturing

20%

20%

30%

30%

(*) Company expectations and approximate percentages 7

PRO

PRIE

TARY

PR

ODU

CTS

2016E Sales$1.49-$1.51

billion

The customers we serve

8

2016 Expected Organic

Sales Growth 6-8%

20%

20%

30%

30%

Biologics

Contract Manufacturing

Pharma

Generics

Source: Company expectations and approximate percentages

More than 2,000

customers

Global customer

base

About 2,400 injectable products are in the

development pipeline

Top 125 customers make up

95% of sales

Proprietary Products

StoppersSealsCaps

Syringe ComponentsDaikyo CZ Vials & Syringes

Reconstitution SystemsSelf-Injection Devices

Wests role in delivering medicines to patients

Contract Manufacturing

Engineering

Injection Molding

Project Management

Tooling

$0.3B$1.1B

~8,000 productSKUs

9

Long-term strategy

10

Market Led and Customer Experience

Operational Excellence

Product and Service Differentiation

Drive Shareholder Value

Become the world leader in integrated containment and delivery of injectable medicines

Addressing unique needs

11

Quality A High Bar Set By Our Customers

GENERICS

Speed to market

Efficient manufacturing

BIOLOGICS

Packaging solutions for

sensitive molecules

Self-injection technologies

PHARMA

Total cost of ownership

Life cycle management

Quality manufacturing

Design for manufacturing

CONTRACT-MANUFACTURED

PRODUCTS

Patient Focus

West solutions: Integrated containment & delivery

12

Increasing levels of customer intimacy

Increasing value to West

STERILIZED

WASHED

COATED

ADMINISTERED

CAMERAINSPECTED

QUALITY BY DESIGN

CONTAINMENT

SELFINJECTION

CONTRACT MANUFACTURINGINJECTION MOLDING

CONTRACT MANUFACTURINGMULTI-COMPONENT ASSEMBLY

Circles reflect relative size of 2015 net sales

Standard Packaging

High-Value Components

0%

5%

10%

15%

20%

0% 30% 60%

2015 Category Gross Margin %

Proprietary Devices

Contract Manufacturing

2015 GM 32.6%5-Yr Sales CAGR 6.7%

Product net sales & margin growth2011-2015 compound annual net sales growth rates (excludes currency)

> High-Value components have driven growth

> Proprietary devices present significant growth opportunity

> Steady Contract Manufacturing and standard packaging businesses

5-Ye

ar C

AGR

13

0%

Deep technical expertise

14

~2,500Employees have worked 10+ years

>65Projects in

development

>850Issued patents and

pending patent applications

12Number of R&DInnovation Sites

Innovation & TechnologyCurrent Developments

15

Container Systems NovaPure 1-3 mL Verux launch Flip-Off Seal RS/RU Crystal Zenith platform

launches

Delivery Systems SmartDose development Innovation Center in Israel Patient-centric approach

West solutions: Next generation delivery

16

Customization

Dosages ranging from 1 mL 10 mL

Preloaded & pre-sterilized

Patient-centric approach

Customer process simplification

First quarter 2016 summary results($ millions, except earnings per-share (EPS) data)

17(1) Please refer to Reconciliation of Non-GAAP Measures at the end of these materials for more information.

Three Months Ended March 31,

2016 2015 Reported Net Sales $362.1 $335.9 Net Sales at Constant Currency(1) $371.2 $335.9 Gross Profit Margin 34.0% 32.7% Reported Operating Profit $30.0 $47.8 Adjusted Operating Profit(1) $55.6 $47.8 Diluted EPS $0.30 $0.45 Adjusted Diluted EPS(1) $0.53 $0.45

10.5% constant-currency sales growth

Excluding adverse currency impact of approximately $0.02,Adjusted Diluted EPS grew 24%

($ millions, except per-share data)

Three Months Ended

September 30March 31,

20152016

20142015

Reported Net Sales

$ 344.5362.1

$ 355.9335.9

Net Sales at Constant Currency(1)

$ 374.5371.2

$ 355.9335.9

Gross Profit Margin

31.434.0%

30.932.7%

Reported Operating Profit

($ 3.5)30.0

$ 44.047.8

Adjusted Operating Profit(1)

$ 45.555.6

$ 45.247.8

Diluted EPS

$ 0.300.02

$ 0.430.45

Adjusted Diluted EPS(1)

$ 0.440.53

$ 0.440.45

18

Proprietary Products, 80% of total sales

BIOLOGICS

Double-digit organic sales growth

GENERICS

Double-digit organic sales growth

PHARMA

Mid-single digit organic sales growth

Low-single digit organic sales growth

CONTRACT-MANUFACTURED

PRODUCTS

Q1 2016 Highlights

20% of total

High-Value Product Offerings +22% organic sales growth

2016 Full-year guidance ($ millions, except EPS - Non-GAAP) (1) (2)

19

Estimated 2016 Revenue

Estimated Gross Profit %

Proprietary Products $1,180 - $1,190 37.7% to 38.2%

Contract-Manufactured Products $310 - $320 17.4% to 18.4%

Consolidated $1,490 - $1,510 33.5% to 34.0 %

Est. Capital Spending $150 - $175

Est. Adjusted Diluted EPS (1) $2.12 to $2.25 per share

Est. Reported Diluted EPS (1) (2) $1.76 to $1.99 per share

(1) Guidance includes various currency exchange rate assumptions, most significantly the Euro at $1.12 for the remainder of 2016.Actual results will vary as a result of variability of exchange rates, among other items.

(2) Estimated reported diluted EPS includes estimated restructuring charges of $0.23 to $0.28 per share and estimated Venezuela currency devaluation charge of $0.03 to $0.08 per share.

20

Strong Operating Cash FlowCapital Allocation Priorities: Investing in our business Dividends Inorganic growth Debt repayment Stock repurchase

Cash-flow and allocation

Artist rendering: new plant in Waterford, Ireland

Building for the Future

Market-led strategy addressing the specific needs of pharmaceutical, biotechnology, generic and medical device customers

Strong competitiveposition with high barriers to entry Quality culture

Designed into regulated products

Scientific and technical expertise

Global Operations expanding capacity to meet growing customer demand

Proprietary products and contract manufacturing expected to drive net sales growth and margin expansion

Financial strength to invest

Strong balance sheet and increasing operating cash flow

21

Innovations in integrated containment and delivery driving new products and services for long-term growth

Create Value for Customers, Patients, Employees and Shareholders

Appendix:Reconciliation of non-GAAP measures

22

2015 2014 2013 2012 2011

Diluted EPS Reported (GAAP) $1.30 $1.75 $1.57 $1.15 $1.08

Pension settlement charge 0.43 - - - -

Executive retirement and related costs 0.09 - - - -

License costs - 0.01 - - -

Discrete tax items 0.01 0.02 0.06 0.03 0.02

Restructuring, impairment and related charges - - - 0.05 0.05

Acquisition-related contingencies - - - 0.01 (0.01)

Extinguishment of debt - - - 0.14 -

Special separation benefits - - - - 0.03

Diluted EPS Adjusted (Non-GAAP) $1.83 $1.78 $1.63 $1.38 $1.17

Reconciliation of Net Sales to Net Sales at Constant Currency(1)

(1) Net sales at constant currency translates the current-period reported sales of subsidiaries whose functional currency is other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period.

($ million, except EPS data)Reconciliation of Reported and Adjusted Operating profit, Net Income and Diluted EPS

23

Three months ended March 31, 2016Operating

profit

Income tax

expenseNet

incomeDiluted EPS

Reported (GAAP) $30.0 $6.9 $22.1 $0.30Restructuring and related charges 22.9 7.9 15.0 0.20Venezuela currency devaluation 2.7 0.2 2.5 0.03Adjusted (Non-GAAP) $55.6 $15.0 $39.6 $0.53

Three months ended March 31, 2016 Proprietary CM Eliminations TotalReported net sales (GAAP) $290.8 $71.6 $(0.3) $362.1Effect of changes in currency translation rates 8.9 0.2 - 9.1Net sales at constant currency (Non-GAAP)(1) $299.7 $71.8 $(0.3) $371.2

Appendix:Reconciliation of non-GAAP measures

(1) Please refer to Notes to Non-GAAP Financial Measures in Wests April 28, 2016 press release.

(2) Guidance includes various currency exchange rate assumptions, most significantly the Euro at $1.12 for theremainder of 2016. Actual results will vary as a result of exchange rate variability.

Reconciliation of adjusted diluted EPS guidance to reported diluted EPS guidance

24

Full Year 2016 Guidance(1) (2)

Adjusted diluted EPS guidance $2.12 to $2.25Estimated restructuring chargesEstimated currency devaluation (Venezuela)

(0.23 to 0.28)(0.03 to 0.08)

Reported diluted EPS guidance $1.76 to $1.99

Appendix:Reconciliation of non-GAAP measures

West Pharmaceutical Services, Inc.Safe harbor statement Our missionInjectable market An integral part of the healthcare industry Components manufacturedWest business at a glanceThe customers we serveWests role in delivering medicines to patientsLong-term strategyAddressing unique needsWest solutions: Integrated containment & deliverySlide Number 13Deep technical expertiseInnovation & TechnologyCurrent DevelopmentsWest solutions: Next generation deliveryFirst quarter 2016 summary results($ millions, except earnings per-share (EPS) data) Q1 2016 Highlights2016 Full-year guidance ($ millions, except EPS - Non-GAAP) (1) (2)Cash-flow and allocationBuilding for the FutureAppendix:Reconciliation of non-GAAP measuresAppendix:Reconciliation of non-GAAP measuresAppendix:Reconciliation of non-GAAP measures